Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients
Authors:
- Markus LeffersMLMarkus Leffers
- Johanna HerbstJHJohanna Herbst
- Jolanthe KropidlowskiJKJolanthe Kropidlowski
- Katharina PrieskeKPKatharina Prieske
- Anna Lena BohnenABAnna Lena Bohnen
- Sven PeineSPSven Peine
- Anna JaegerAJAnna Jaeger
- Leticia Oliveira-FerrerLOLeticia Oliveira-Ferrer
- Yvonne GoyYGYvonne Goy
- Barbara SchmalfeldtBSBarbara Schmalfeldt
- Klaus PantelKPKlaus Pantel
- Linn WölberLWLinn Wölber
Open Access
Abstract
Cervical cancer is the fourth most common cancer in women, which is associated in >95% with a high-risk human papillomavirus (HPV) infection. Methylation of specific genes has been closely associated with the progress of cervical high-grade dysplastic lesions to invasive carcinomas. Therefore, DNA methylation has been proposed as a triage for women infected with high-risk HPV. Methylation analyses of cervical cancer tissue have shown that cell adhesion molecule 1 (CADM1) and myelin and lymphocyte protein (MAL) methylation are present in over 90% of all cervical high-grade neoplasias and invasive cervical cancers. Here, we established a liquid biopsy-based assay to detect MAL and CADM1 methylation in cell free (cf)DNA of cervical cancer. Methylation of the target gene was validated on bisulfite converted smear-DNA from cervical dysplasia patients and afterward applied to cfDNA using quantitative real-time PCR. In 52 smears, a combined analysis of CADM1 and/or MAL (CADM1/MAL) showed methylation in 86.5% of the cases. In cfDNA samples of 24 cervical cancer patients, CADM1/MAL methylation was detected in 83.3% of the cases. CADM1/MAL methylation was detected already in 81.8% of stage I-II patients showing the high sensitivity of this liquid biopsy assay. In combination with a specificity of 95.5% towards healthy donors (HD) and an area under the curve (AUC) of 0.872 in the receiver operating characteristic (ROC) analysis, CADM1/MAL cfDNA methylation detection might represent a novel and promising liquid biopsy marker in cervical cancer.Keywords
Funding Information
- AiF GmbH (#ZF4665601SB8)
- Werner Otto Stiftung
This publication has 38 references indexed in Scilit:
- Epigenetics and cervical cancer: from pathogenesis to therapyTumor Biology, 2014
- Combined Promoter Methylation Analysis of CADM1 and MAL: An Objective Triage Tool for High-Risk Human Papillomavirus DNA–Positive WomenClinical Cancer Research, 2011
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors2011
- Combined CADM1 and MAL promoter methylation analysis to detect (pre‐)malignant cervical lesions in high‐risk HPV‐positive womenInternational Journal of Cancer, 2010
- CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the diseaseInternational Journal of Cancer, 2010
- Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferationNature Reviews Molecular Cell Biology, 2008
- Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancerBreast Cancer Research and Treatment, 2007
- CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patientsInternational Journal of Cancer, 2003
- Promoter Methylation of TSLC1 and Tumor Suppression by Its Gene Product in Human Prostate CancerJapanese Journal of Cancer Research, 2002
- Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell isCell, 1975